Sign in

    Luca Issy

    Senior Biotechnology Research Analyst at RBC Capital Markets

    Luca Issi, Ph.D., is a Senior Biotechnology Research Analyst at RBC Capital Markets, specializing in biotech company coverage with a focus on innovative gene therapy, medical devices, specialty pharma, and tools and diagnostics. He covers a broad range of biopharmaceutical companies, leveraging his deep industry expertise honed through previous roles at Bain Capital Life Sciences, where he led private and public investments, and at Cowen and Company, covering large-cap pharmaceuticals. Joining RBC in 2020, Issi maintains a strong track record for sector analysis and investment recommendations, supported by his advanced academic credentials including a Ph.D. in Biotechnology and summa cum laude honors in graduate and undergraduate biotechnology studies. He brings significant credibility through his scientific background and buy-side investment experience.

    Luca Issy's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership

    Luca Issy's questions to ARROWHEAD PHARMACEUTICALS (ARWR) leadership • Q3 2025

    Question

    Luca Issy's representative inquired about the initial presentation of plozasiran, asking if it will be a prefilled syringe and what the timeline is for developing an auto-injector.

    Answer

    SVP Andy Davis confirmed the initial launch for FCS will use a prefilled syringe. Interim Chief Medical Scientist Bruce Given added that an auto-injector is being developed for the SHTG indication and is expected to be available at or soon after that launch.

    Ask Fintool Equity Research AI